Amolyt Pharma Announces Research Agreement 

• Amolyt to advance pre-clinical development of anti-PTHR1 monoclonal antibodies as potential treatments of primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM)

• Amolyt has obtained the option to license one or more candidates from XOMA for further clinical development worldwide

• PHPT and HHM are rare endocrine diseases with high unmet needs and these candidates from XOMA represent a natural expansion of Amolyt’s current development pipeline

LYON, France, and Cambridge, MA, January 24, 2023 – Amolyt Pharma (“Amolyt,” “Amolyt Pharma” or the “Company”), a global company specialized in developing innovative therapies for rare endocrine and related diseases, today announced that the Company has entered into a research agreement and licensing option with XOMA Corporation (“XOMA”) for the pre-clinical evaluation of a select set of monoclonal antibodies that arose from XOMA’s legacy discovery efforts as potential treatments for primary hyperparathyroidism (“PHPT”) and humoral hypercalcemia of malignancy (“HHM”). Amolyt has the option to license one or more of these candidates from XOMA for further clinical development worldwide.

Read the press release